Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche And Curadev Sign IDO1/TDO Pact

by Lisa M. Jarvis
April 27, 2015 | A version of this story appeared in Volume 93, Issue 17

Roche is paying Curadev Pharma $25 million up front as part of a research pact to develop small molecules that block IDO1 and TDO, enzymes that help cancer cells hide from the immune system. New Delhi-based Curadev also gets research funding and could reap up to $530 million in milestones if IDO1/TDO inhibitors reach the market. Last October, Roche’s Genentech unit paid NewLink Genetics $150 million for access to its IDO1 inhibitor NLG919.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.